In recent years, immune-based therapies have become an increasingly attractive treatment option for patients with cancer. Cancer immunotherapy is often used in combination with conventional chemotherapy for synergistic effects. The alkylating agent cyclophosphamide (CTX) has been included in various chemoimmunotherapy regimens due to its well-known immunostimulatory effects. Paradoxically, CTX can also induce suppressor cells that inhibit immune responses. However, the identity and biological relevance of these suppressor cells are poorly defined. Here we report that CTX treatment drives the expansion of inflammatory monocytic myeloid cells (CD11b Besides CTX, we found that melphalan and doxorubicin can also induce monocytic myeloid suppressor cells. These findings reveal a counter-regulation mechanism elicited by certain chemotherapeutic agents, and highlight the importance of overcoming this barrier to prevent late tumor relapse after chemoimmunotherapy.
Abstract
In recent years, immune-based therapies have become an increasingly attractive treatment option for patients with cancer. Cancer immunotherapy is often used in combination with conventional chemotherapy for synergistic effects. The alkylating agent cyclophosphamide (CTX) has been included in various chemoimmunotherapy regimens due to its well-known immunostimulatory effects. Paradoxically, CTX can also induce suppressor cells that inhibit immune responses. However, the identity and biological relevance of these suppressor cells are poorly defined. Here we report that CTX treatment drives the expansion of inflammatory monocytic myeloid cells (CD11b substantiated by the finding that many widely used chemotherapeutic agents have immunomodulatory effects (3) . One complicated issue associated with chemoimmunotherapy strategy is that chemotherapy causes substantial cell death and tissue injuries, which often result in dynamic recovery of lymphoid and myeloid cells, along with extensive inflammation in the post-chemotherapy setting. How these events shape the ultimate outcome of immunotherapy is not fully understood.
The antineoplastic agent cyclophosphamide (CTX) is frequently used in the treatment of hematopoietic malignancies. More importantly, CTX represents a well-studied example of chemotherapeutic agent with strong immunomodulatory effects. At high doses, CTX is cytotoxic and lymphoablative, causing severe immune suppression. At lower doses, CTX exhibits multifaceted immune-potentiating effects (4, 5) . It has been shown that CTX can induce immunogenic tumor cell death that enhances antigen presentation (6) , and mitigate immunosuppression by reducing the number and activity of T regulatory cells (7) . In addition, CTX induces transient lymphopenia, creating niche-"space" and providing growth factors for the
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Author Manuscript Published OnlineFirst on April 29, 2014 ; DOI: 10.1158/0008-5472.CAN- expansion and survival of transfused tumor-reactive T lymphocytes (8) . Thus, the postchemotherapy period represents a window of opportunity to exploit for immunotherapy, especially adoptive T-cell therapy (9, 10) . Despite CTX's well-characterized immunostimulatory effects, it has long been documented that CTX can induce a population of cells exhibiting immunosuppressive activities (11, 12) . Some early studies suggested that CTX-induced suppressor cells were a heterogeneous population with CD11b + myeloid lineage cells being most suppressive (13, 14) . Recent studies reported that CTX-induced suppressor cells were 100 μg per injection), respectively, was i.p. injected to mice following the specified schedule.
CCX872 was given to mice by daily s.c. injection for 14 days, starting 4 days after CTX treatment. In vivo PD-1 and PD-L1 antibody blockade was conducted as described previously (19) .
In vitro suppression assay. Research. 
Results

Chemoimmunotherapy with CTX+CD4 AT induces inflammatory myeloid cells consisting of monocytic and granulocytic subsets
Using a mouse model of B-cell lymphoma, we previously reported that adoptive transfer (AT) of tumor-specific CD4+ T cells after CTX treatment gave rise to polyfunctional CD4+ effector cells, which played a critical role in mounting a robust antitumor immune response (18) .
However, antitumor CD4+ effector cells were susceptible to functional tolerization in the face of persistent residual tumors. Consequently, the antitumor immunity elicited by chemoimmunotherapy was not durable, and most mice succumbed to tumor relapse (19) Fig. S1 ) of CD11b+ cells. In contrast, the presence of CD11b+ myeloid cells was markedly increased in mice treated with the combination of CTX and CD4 AT (Fig. 1A and Supplementary Fig. S1 , CTX+CD4 AT). These CD11b+ cells mainly consisted of two subpopulations expressing varied levels of myeloid lineage markers Ly6C, Ly6G and Gr1 (Fig.   1B left) subset expressed higher levels of CD14 and IL4Rα compared to the granulocytic myeloid subset (Fig. 1C) .
The robust expansion of myeloid cells suggested that these cells were proliferative.
Indeed, both subsets of myeloid cells expanded after CTX+CD4 AT were Ki67 positive (Fig.   1D ). Interestingly, the monocytes in both spleen and tumor exhibited higher Ki67 levels than the granulocytes, suggesting that the former population had a proliferative advantage. Moreover, as we reported previously (19) , the CTX+CD4 AT regimen resulted in heightened inflammation, as evidenced by markedly elevated levels of IL1β, CSF1, CXCL10, CXCL12 and CCL2
( Supplementary Fig. S2 ). Corresponding to this inflammatory immune milieu, the monocytes in both spleen and tumor expressed high levels of CCR2 (Fig. 1E ), a key chemokine receptor involved in mediating the trafficking of inflammatory monocytes (20) .
Post-therapy expansion of myeloid cells is driven by CTX, and intensified by tumorspecific CD4+ effector cells
To determine which component of the treatment regimen (CTX or CD4 AT) led to the induction and expansion of myeloid cells, we quantified the two myeloid cell subsets in mice receiving different treatment. We first compared the frequency of each myeloid subset in treated or untreated tumor-bearing mice. The frequencies of monocytes in untreated mice were low in the spleen and tumor, and were not increased in mice receiving tumor-specific CD4+ T cells Next we conducted time course experiments to determine the kinetics of myeloid cell expansion after treatment. The absolute numbers of the two subsets of myeloid cells were used to reflect the actual cell accumulation in specified tissues. In the spleen, there was an initial reduction in the numbers of monocytes after CTX treatment (day 2) followed by a rebound thereafter ( Fig. 2D upper panel, CTX) . In the tumor, the rebound of monocytes peaked on day 7, and by day 10 reached a stable level that was elevated than the starting point ( showed that in mice with established tumors, the transferred tumor-specific CD4+ T cells were destined to become dysfunctional and suppressive, but CTX allowed these cells to differentiate into activated effector cells (18) . Thus, antigen-driven CD4+ T-cell effector differentiation might be a prerequisite for enhanced myeloid cell expansion. Consistent with this idea, adoptive transfer of irrelevant DO11.10 CD4+ T cells (OVA-specific) after CTX did not boost myeloid cell expansion compared to CTX only (data not shown). Altogether, the data indicate that CTX is necessary and sufficient to drive systemic myeloid cell expansion in tumor-bearing hosts, and that activated tumor-specific CD4+ effector cells can amplify this expansion.
Therapy-induced monocytic myeloid cells possess immunosuppressive activities
To determine whether therapy-induced myeloid cells possessed immunosuppressive activities, we conducted in vitro suppression assays to test the ability of each myeloid cell subset to suppress CD4+ T-cell activation. Using a CFSE dilution assay as the readout for cell proliferation, Fig. 3A shows that CD4+ T-cell response to non-specific stimuli (αCD3 and αCD28 mAbs) was inhibited, in a dose dependent manner, by monocytes isolated from the spleens of mice receiving the CTX+CD4 AT regimen, whereas granulocytes from the same mice were not suppressive. Similarly, monocytes recovered from the tumors of treated mice were immunosuppressive, whereas tumor-infiltrating granulocytes were nonsuppressive (Fig. 3B) .
The immunosuppressive activities of monocytes were also confirmed by 3 H-thymidine incorporation assays (Supplementary Fig. S4A ). Furthermore, therapy-induced monocytes can also suppress CD4+ T-cell activation in response to antigen-specific stimulation ( Supplementary   Fig. S4B ).
We asked whether the emergence of immunosuppressive monocytes after therapy was peculiar to the tumor microenvironment, or the presence of tumor-specific CD4+ T cells. To address this, naïve mice (tumor-free) were treated with a single dose of CTX, and spleen cells were harvested at different time points to enumerate the numbers of monocytic and granulocytic myeloid cells. Fig. 3C shows that the numbers of monocytic and granulocytic myeloid cells were both reduced shortly after CTX, reaching the nadir by day 2 and day 4, respectively; and both populations rebounded thereafter, resulting in net increases in cell number by day 10. Induction of myeloid cell expansion was seen in mice receiving CTX treatment in the range of 100-300 mg/kg ( Supplementary Fig. S5 ). In vitro suppression assays showed that the monocytes, but not granulocytes, from CTX-treated tumor-free mice can suppress CD4+ T-cell activation (Fig. 3D right). As controls, neither subset of myeloid cells from the spleens of untreated naïve mice was suppressive (Fig. 3D left) , suggesting that immunosuppression is an acquired property of monocytic myeloid cells induced by CTX.
We then extended the above assays to some other chemotherapeutic agents to determine whether induction of immunosuppressive monocytes was a unique feature of CTX.
We found that the frequencies of monocytic myeloid cells also increased in mice treated with melphalan (Mel) or doxorubicin (Dox) (Supplementary Fig. S6A ), and these cells were equally S6B). Altogether, the data indicate that certain cytotoxic anticancer drugs can induce the expansion of immunosuppressive monocytes which phenotypically resemble the well-described monocytic myeloid-derived suppressor cells (mMDSCs) (17) .
Therapy-induced monocytes inhibit CD4+ T-cell activation through the PD-1/PD-L1 axis
We then sought to dissect the mechanism(s) by which therapy-induced inflammatory monocytes mediated immune suppression. A number of molecules, including Arginase 1, iNOS, IDO, IFNγ, IL-10 and TGFβ, have been implicated in suppression mediated by inflammatory monocytes or MDSCs (17, 21) . We repeated in vitro suppression assays with the addition of inhibitors or neutralizing mAbs targeting these molecules. However, these inhibitors used either individually or in combination had no significant effects on monocyte-mediated suppression (data not shown). Since the co-inhibitory molecule PD-L1 was prominently expressed in inflammatory monocytes (Fig. 4A) , we hypothesized that the PD-1 pathway might be involved in monocyte-mediated suppression. To test this, we used two complementary approaches to disrupt PD-1/PD-L1 interactions. First, therapy-induced monocytes were co-cultured with PD-1-sufficient (WT) CD4+ T cell responders in the presence of a PD-1/PD-L1 blocking mAb cocktail.
PD-1/PD-L1 blockade largely restored proliferation of the responder cells (Fig. 4B left) . The second approach used PD-1-deficient (PD-1KO) CD4+ T cells as responders. Strikingly, therapy-induced monocytes, which efficiently suppressed PD-1-sufficient CD4+ T cell responders, were unable to suppress the proliferation of PD-1-deficient CD4+ T cells (Fig. 4B right). Together, the data support the notion that the PD-1/PD-L1 pathway is involved in monocyte-mediated suppression on CD4+ T cells.
PD-1 blockade after CTX+CD4 therapy leads to persistence of CD4+ effector cells and durable antitumor effects
Research. Our in vitro suppression data (Fig. 4B) suggested that disruption of the PD-1/PD-L1 pathway may prevent CD4+ effector cell tolerization in vivo. To test this, tumor-bearing mice were treated with CTX followed by adoptive transfer of either PD-1-sufficient (WT) or PD-1-deficient (PD-1KO) tumor-specific CD4+ T cells. Fig. 5A shows that there were similar levels of monocytic and granulocytic myeloid cells in mice that received PD-1KO CD4+ T cells compared to those that received WT CD4+ T cells after CTX. Nonetheless, the transferred PD-1KO CD4+ T cells persisted in mice and maintained a polyfunctional effector phenotype, i.e. and lack of production of pro-inflammatory cytokines (Fig. 5B) . Correspondingly, adoptive transfer of PD-1KO CD4+ T cells after CTX resulted in prolonged survival in the majority of mice, whereas relapse was prevalent in mice receiving WT CD4+ T cells after CTX ( then reducing the presence of these cells should confer significant therapeutic benefits. Our finding that therapy-induced monocytes were highly proliferative (Fig. 1D) suggested that these cells may be more sensitive to low-dose chemotherapy. We chose to test this using T-cell transfer reduced the frequency and number of therapy-induced monocytes in peripheral blood, spleen and tumor (Fig. 6A-B) . Interestingly, reduction of granulocytes was also evident in blood and spleen, but was insignificant in tumor. Notably, reduction of therapy-induced monocytes correlated with remarkable therapeutic benefits. As shown in Fig. 6C-D We demonstrated in the A20HA tumor model that 5-FU can effectively reduce the presence of therapy-induced monocytes ( Supplementary Fig. S8 ), further supporting the notion that therapyinduced immunosuppressive monocytes are sensitive to certain anticancer drugs used at low dose.
Disrupting the CCL2-CCR2 axis after CTX+CD4 AT therapy leads to targeted depletion of inflammatory monocytes and prevention of relapse
We sought to more specifically deplete therapy-induced monocytes so as to determine their role in CD4+ effector cell tolerization and tumor relapse. Based on our finding that therapy- 
induced monocytes preferentially expressed high levels of CCR2 (Fig. 1E) , we administered a CCR2-specific mAb (MC21) to mice after CTX+CD4 AT therapy. Anti-CCR2 mAb injection led to selective depletion of CD11b + Ly6C hi monocytes in peripheral blood, spleen and tumor, whereas granulocytes (CD11b + Ly6C low ) were largely unaffected (Fig. 7A second row) . For comparison, a Ly6G-specific mAb (clone 1A8) was used to selectively deplete granulocytes but spare monocytes (Fig. 7A bottom row) . The functional impact of selective depletion of monocytes or granulocytes on the efficacy of chemoimmunotherapy was assessed by tumor growth and mouse survival. The CTX+CD4 AT regimen led to initial tumor regression followed by relapse in most mice (Fig. 7B third graph, 7 out of 8 mice had relapse). Depletion of inflammatory monocytes, by administering αCCR2 mAb after CTX+CD4 AT therapy, resulted in uniform and complete tumor regression in all mice, and substantially reduced the occurrence of relapse ( Fig.   7B fourth graph, 3 out of 11 mice had relapse). By contrast, depletion of granulocytes appeared to accelerate tumor regrowth (Fig. 7B last graph) . It is important to note that the combination of CTX and αCCR2 mAb was not different from CTX alone (Fig. 7B first and second graphs) , suggesting that αCCR2 mAb by itself was not toxic to tumor cells which were CCR2 negative (data not shown), and that the beneficial effects afforded by CCR2-specific mAb require the presence of tumor-specific CD4+ effector cells. In line with the tumor growth data, the survival results clearly demonstrated that selective depletion of therapy-induced monocytes promoted, whereas depletion of granulocytes impaired, long-term survival of tumor-bearing mice (Fig. 7C) .
Moreover, the transferred CD4+ T cells were readily detectable in cured mice, and maintained an effector phenotype (data not shown). As an alternative approach, we replaced CCR2-specific mAb with CCX872, a potent and selective antagonist of CCR2. As shown in Fig. 7D , administration of CCX872 following CTX+CD4 therapy significantly improved long-term survival compared to the control mice that received CTX+CCX872. Altogether, our data indicate that disrupting the CCL2/CCR2 axis can effectively relieve tumor-specific CD4+ effector cells from inflammatory monocyte-mediated tolerization and sustain a productive antitumor immunity.
Since many mice had complete tumor remission and survived long-term after CTX+CD4
AT therapy in combination with either CCR2-specific mAb (MC21) or Gem, we asked whether these long-term survivors (LTS) had developed immune memory. To this end, mice that became LTS after combinatorial therapy were re-challenged with A20HA. Fig. 7E shows that these mice were completely protected from tumor re-challenge, whereas all naïve control mice succumbed to rapid tumor growth. (26) (27) (28) . In addition to mediating immune suppression, tumor-induced inflammatory monocytes were also found to facilitate tumor metastasis in breast cancer (29) . Different from these published studies which focus on cancer-induced inflammation, the current study addresses the role of therapy-induced inflammation in regulating ongoing immune responses. Although the tumor-promoting effect of chronic inflammation has been wellestablished (30, 31) , the impact of therapy-induced inflammation (often acute) on eventual treatment outcomes has been a subject of debate (32) . In our study, it was chemotherapy with CTX that drove the expansion of immunosuppressive monocytes, regardless of the presence or absence of tumor. The fact that CTX-induced inflammatory monocytes acquired suppressive activities in the absence of tumor growth (Fig. 3D) suggests that this feature may serve as a negative feedback loop to control excessive inflammation. Surprisingly, this counter-regulation mechanism was reinforced by antitumor CD4+ effector cells in a therapeutic setting (Fig. 2) . It has been shown that CTX induces an inflammatory immune milieu, in which myeloid growth factors and chemotactic factors such as GM-CSF, G-CSF, and CCL2 are abundant (8, 33, 34) .
We previously showed that this inflammatory milieu was markedly intensified in the presence of CD4+ effector cells (19) . It is intriguing that CTX-induced monocytes shared some similarities In addition to CTX, we showed that at least two other anticancer drugs, doxorubicin and melphalan, can induce the expansion of monocytic myeloid suppressor cells ( Supplementary   Fig. S6 ). This is consistent with the report by Nakasone et al that doxorubicin treatment led to a specific, acute recruitment of CCR2+ monocytic myeloid cells that contributed to tumor regrowth Altogether, these studies indicate that a broad spectrum of cancer therapies may give rise to inflammatory myeloid suppressor cells that counteract therapy efficacy.
Although the current study focused on monocyte-mediated suppression on antitumor CD4+ T cells, it is worth noting that CD8+ T-cell activation was also inhibited by CTX-induced inflammatory monocytes (data not shown). Therefore, it is reasonable to speculate that targeting therapy-induced myeloid suppressor cells may augment the long-term efficacy of some current cancer immunotherapy strategies, such as cancer vaccines and adoptive T-cell therapy, in which CTX is often a component of the treatment regimen. From a therapeutic standpoint, our study outlines multiple targeted approaches that can effectively reduce the number or abolish the suppressive function of inflammatory monocytes, thereby tipping the balance toward unrestrained antitumor immunity. Here we showed that the proliferative nature of inflammatory monocytes rendered them susceptible to low dose gemcitabine and 5-FU. Alternatively, disrupting the relevant CCL2/CCR2 chemotactic pathway represents an attractive approach to reduce the recruitment and accumulation of inflammatory monocytes (Fig. 7) . Along this line, the use of CCL2-specific neutralizing mAb or small molecule inhibitors for CCR2 has also shown beneficial effects in several preclinical models (29, 40, 41, 43) . A novel finding of our study is that therapy-induced inflammatory monocytes suppress CD4+ T-cell responses through the PD-1/PD-L1 axis. This provides a mechanistic explanation for our previous observation that the PD- 
1 pathway is critically involved in CD4+ effector cell tolerization (19) . Although A20 tumor cells constitutively express PD-L1, it has been shown that direct encounter of A20 tumor cells in vivo was stimulatory, rather than tolerogenic, to the activation of tumor-specific CD4+ T cells (44).
Here we showed that targeted depletion of inflammatory monocytes was quite effective in preventing PD-1-dependent CD4+ T cell tolerization (Fig. 7) , supporting the notion that the relevant ligands for PD-1 primarily come from inflammatory monocytes as oppose to tumor cells.
In summary, our study reveals that inflammation engendered after chemoimmunotherapy may facilitate tumor escape by engaging myeloid suppressor cells that attenuate antitumor immunity, and that mitigating this counter-regulation mechanism can augment the efficacy of chemoimmunotherapy. We have identified multiple clinically applicable approaches that can effectively target chemotherapy-induced myeloid suppressor cells, leading to durable antitumor immunity. These findings imply that modulation of therapy-induced inflammation represents an attractive strategy to augment the efficacy of chemoimmunotherapy and achieve a long-lasting curative effect.
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